Change of Auditor
For immediate release
8 August 2022
("Alliance", "Company" or the "Group")
Change of Auditor
Alliance Pharma plc (AIM: APH), the international healthcare group, announces that, following a tender process, it has appointed Deloitte LLP ("Deloitte") as its auditor for the financial year ending 31 December 2022. KPMG LLP ("KPMG"), its outgoing auditor of six years, did not participate in this tender process.
KPMG has submitted to the Company, in accordance with section 519 of the Companies Act 2006, a letter stating its reason for resigning. A copy of KPMG's letter has, in accordance with section 520 of the Companies Act 2006, today been sent to all shareholders, along with an explanatory letter from the Company. Both letters can be found at this link:
Any proposal to re-appoint Deloitte as auditor for the financial year ending 31 December 2023 will be subject to approval by the Group's shareholders at the Company's Annual General Meeting to be held in 2023.
For further information:
Alliance Pharma plc
+ 44 (0)1249 466966
Cora McCallum, Head of Investor Relations & Corporate Communications
+ 44 (0)1249 705168
+ 44 (0)20 7466 5000
Mark Court / Hannah Ratcliff
Numis Securities Limited
+ 44 (0)20 7260 1000
Nominated Adviser: Freddie Barnfield / Duncan Monteith
Corporate Broking: James Black
Investec Bank plc
+ 44 (0)20 7597 5970
Corporate Finance: Daniel Adams
Corporate Broking: Patrick Robb
Alliance Pharma plc (AIM: APH) is an international healthcare group. Our purpose is to improve the lives of consumers and patients through making available a range of clinically valuable healthcare products.
Our core focus is on the marketing of Consumer Healthcare brands, complemented by a smaller Prescription Medicines business. In total, we hold marketing rights to around 80 brands, with revenues generated from a mix of direct, distributor and e-commerce sales.
Headquartered in the UK, the Group employs around 250 people based in locations across Europe, North America, and the Asia Pacific region. By outsourcing our manufacturing and logistics operations, we remain asset-light and focused on maximising the value of our brands.
For more information on Alliance, please visit our website: www.alliancepharmaceuticals.com